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ABSTRACT
Background and Objectives: Pulmonary arterial hypertension (PAH) is a life threatening disease characterized by progres-
sive pulmonary arterial occlusion which may ultimately result in death. Currently, the available treatments are diverse, but no 
therapy alone can reverse the disease process although they may have some clinical benefits. This study was designed to investi-
gate single and combination therapy of simvastatin and sildenafil, which have different mechanisms of action, in monocrota-
line (MCT)-induced PAH. Meterials and Methods: Rats were randomized to receive saline (control, n=8) or MCT treatment 
(n=32). MCT treated rats were randomized to vehicle, simvastatin (2 mg/kg/day), sildenafil (25 mg/kg/day) and a combina-
tion simvastatin and sildenafil (n=8, respectively). Three weeks later, hemodynamic study and histologic changes of pulmo-
nary arterioles were measured. Proliferating cell nuclear antigen (PCNA) as well as Western blot for endothelial nitric oxide 
synthase (eNOS) were performed. Results: Systolic right ventricular pressure was significantly decreased in monotherapy 
groups (simvastatin and sildenafil) and the combination group compared to MCT group (p<0.05). Right ventricular hypertro-
phy and medial wall thickness of pulmonary arterioles were significantly attenuated with sole and combination therapy (p< 
0.05). However, combination therapy did not confer additive benefits over monotherapy. Altered PCNA or eNOS in lung tis-
sue was normalized by either monotherapy or combination therapy. Conclusion: The results suggest that either simvastatin 
or sildenafil has the therapeutic potential in MCT-induced PAH, although combination therapy of these two drugs has failed 
to show greater benefits in the study. (Korean Circ J 2010;40:659-664)
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Introduction
Pulmonary arterial hypertension (PAH) is characterized 
by abnormal proliferation of vascular endothelial and smooth 
muscle cells and causes occlusion of pulmonary arterioles wh-
ich eventually results in right heart failure and death.
1-3) Alth-
ough there is no cure for PAH, newer medical therapies have 
been shown to improve a variety of clinical end-points, includ-
ing survival rate, exercise tolerance, hemodynamics and quali-
ty of life measures.
4)
Basically, there are three classes of medications that produ-
ce benefits in PAH: prostanoids, endothelin receptor antago-
nists, and phosphodiesterase-5 (PDE-5) inhibitors.
5) Although 
they have clinical benefits, these currently available therapies 
can not reverse the disease process itself.
5) Therefore, new ther-
apies based on the understanding of the PAH pathophysiol-
ogy, especially directed at suppressing inappropriate cellular 
proliferation in pulmonary arteries, are warranted. The addi-
tion a drug with different mechanisms may be reasonable in 
the event of suboptimal response to monotherapy.
2)4) 
Simvastatin is a well known drug that confers cardiovascu-
lar benefits that exceed its effects in lowering serum cholester-
ol.
6) Recently, it has been demonstrated that simvastatin can re-
verse established severe PAH and improve survival, and atten-
uate vascular remodeling in the animal models of pulmonary 
hypertension.
7-10) 
One of the PDE-5 inhibitors, sildenafil, is a common choice 
for decreasing pulmonary arterial pressure and vascular remo-660   Simvastatin, Sildenafil and Combination in PAH
deling in animal model of PAH.
11)12) In addition, sildenafil was 
found to improve pulmonary hemodynamics and exercise ca-
pacity in patients with PAH.
13-16) 
In this study, we evaluated the effect of simvastatin or silde-
nafil treatment in a rat model of monocrotaline (MCT)-induc-
ed PAH. In addition, we investigated whether combination of 
simvastatin and sildenafil would be more effective than the res-
pective monotherapy.
Materials and Methods
Experimental designs
Forty (n=40) male Sprague-Dawley rats (8 weeks old, 180-
200 g) were randomly allocated into five groups (each group, 
n=8): control group was injected with distillated water, MCT 
group was just injected with MCT (60 mg/kg, subcutane-
ously, Sigma Chemical Co, St. Louis, MO, USA), simvastatin 
group was treated with simvastatin (2 mg/kg/day, Hanmi Ph-
armacy, Korea) in MCT, sildenafil group was treated with sil-
denafil (25 mg/kg/day, Pfizer Australia Limited) in MCT, and 
the combination group was treated with simvastatin and sil-
denafil. Each group was kept in the same room and subjected 
to the same light/dark cycle. After 21 days, hemodynamic meas-
urement was conducted and tissue samples were obtained for 
morphometric analysis and Western blot. The experimental 
protocol was reviewed and approved by the Animal Care and 
Use Committee of Dongguk University. Animal care and use 
was in accordance with the guidelines of the National Insti-
tutes of Health (Bethesda, MD).
Measurement of systolic right ventricular pressure
The animals were anaesthetized by intraperitonial injection 
of ketamine (100 mg/kg). For measurement of systolic right ven-
tricular pressure (RVP), the tip of a polyethylene catheter (PE-
50, Becton Dickinson, Franklin Lakes, NJ, USA) was inserted 
into the right ventricle (RV) via the internal jugular vein and a 
fluid-filled catheter was connected to a pressure transducer (Gr-
ass polygraph, Grass instrument Co, Quincy, MA, USA).
Right ventricular hypertrophy and lung morphology
Rats were euthanized by pentothal overdose and then the 
RV free wall was dissected from the left ventricle plus septum 
(LV plus S) and weighed separately on the analytic scale. RV 
hypertrophy (RVH) was assessed by RV-to-LV plus S weight 
ratio. For the analysis of vascular remodeling, the left lung was 
paraffin-embedded after fixation with transcardiac infusion 
of 4% paraformaldehyde. Serial coronal sections in 5 μm thick 
were obtained at the lower zone of the lung. 
Following deparaffinization, sections were stained with 
hematoxylin-eosin (H&E). The medial wall thickness (MWT) 
of the pulmonary arteriole was measured at the size of 50-100 
μm. The MWT ratio, an index of medial wall hypertrophy, was 
determined as the average of 10 to 15 fields per slice and calcu-
lated as below: MWT=(external diameter-internal diameter)/
external diameter.
Immunohistochemical stain of proliferating cell 
nuclear antigen
Sections were stained with the DAKO kit (DAKO, CH). Brie-
fly, endogenous peroxidase activity was blocked with hydro-
gen peroxide. After washing in phosphate buffer saline (PBS), 
the sections were incubated with rat anti-proliferating cell nu-
clear antigen (PCNA) (1 : 1,000, Sigma, St. Louis, MO, USA). 
After washing in PBS, the sections were then incubated with 
biotylated universal anti-mouse, -goat and -rabbit immuno-
globulins. 
After washing, the sections were incubated with streptavi-
din conjugated to horseradish peroxidase and reacted with a 
solution containing diaminobenzidine (DAB) and hydrogen 
peroxide. The sections were then counter-stained with Mayer’s 
hematoxylin to visualize cell nuclei. 
Terminal deoxynucleotidyl transferase dUTP nick 
end labeling staining 
Transferase dUTP nick end labeling (TUNEL) staining (Ap-
opTag kit, Intergen) was employed for the detection of deoxy-
ribonucleic acid fragmentation and apoptotic bodies in lung 
tissue. Briefly, after deparaffinizing the sections, digesting pro-
tein using proteinase K and quenching endogenous peroxi-
dase activity with H2O2 in PBS, slides were placed in equili-
bration buffer and then in working terminal deoxynucleotidyl 
transferase (TdT) enzyme, followed by stop/wash buffer. After 
two drops of anti-digoxigenin-peroxidase were applied to the 
slides, peroxidase was detected with DAB and examined un-
der microscope (Olympus Bx20). Negative controls were per-
formed using distilled water or PBS for TdT enzyme in prep-
aration for working TdT. 
Western blotting of endothelial nitric oxide synthase 
Lung tissue was removed and then snap-frozen at -70°C for 
western blot analysis. Tissue samples were homogenized in 
ten volumes of homogenizing buffer. Aliquots were stored at 
-70°C. Samples of homogenate were run on 7.5% polyacryl-
amide mini gels (Bio-Rad Mini Protean). After electrophore-
sis, the protein was transferred to nitrocellulose paper in a Bio-
Rad transblot system. Nitrocellulose sheets were washed and 
incubated with rabbit anti-endothelial nitric oxide synthase 
(eNOS) (Sigma) overnight at 4°C. The labeling was visualiz-
ed with horseradish peroxidase-conjugated secondary antibo-
dies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) with 
an enhanced chemiluminescence (ECL) system (Amersham 
Pharmacia Biotech, Little Chalfont, UK). Immunoblot signal 
developed by ECL system was quantified using Scion Image 
software (version 1.59). Dong Seok Lee, et al.   661
Statistical analysis
All data were presented as mean±standard deviation. Data 
were analyzed by one-way analysis of variance (ANOVA), fol-
lowed by Tukey’s honestly significant different multiple-com-
parison test. Multiple-comparison tests were only applied 
when a significant difference was determined by ANOVA (p< 
0.05). Statistical hypotheses were considered significant if p< 
0.05.
Results
Changes in right ventricular pressure 
RVP was significantly increased in MCT-induced PAH group 
compared to that of the controls (51.5±1.5 vs. 22.2±0.7 mmHg, 
p<0.05), which was markedly suppressed in both single (sim-
vastatin or sildenafil) (32.4±1.2.1, 31.4±1.0 mmHg, p<0.05) 
and combined treatment groups (33.4±0.7 mmHg, p<0.05). 
However, combination therapy was not more effective than 
single therapy with simvastatin or sildenafil (Fig. 1). 
Changes in right ventricular hypertrophy
In the MCT group, RVH was developed and significantly 
increased in RV (LV plus septum ratio) compared to that of the 
controls (0.45±0.03 vs. 0.26±0.02, p<0.05), which was mark-
edly decreased in the simvastatin, sildenafil and combination 
treatment groups (0.32±0.02, 0.34±0.02 and 0.29±0.01, p< 
0.05). Combination therapy tended to diminish RVH more 
effectively than monotherapy, even though it was not statis-
tically significant (Fig. 2). 
 
Changes in pulmonary artery wall thickness 
MCT treatment increased MWT (ratio) of pulmonary arte-
riole compared to that of control (0.34±0.02 vs. 0.08±0.01, p< 
0.05), which was significantly suppressed in the simvastatin, 
sildenafil and the combination treatment groups (0.2±0.01, 
0.19±0.03 and 0.18±0.01, p<0.05) (Fig. 3). However, combi-
nation therapy was not superior to single-agent treatment and 
did not completely reverse pulmonary arterial wall thickness 
to normal. 
Changes in cellular proliferation and apoptosis 
in vascular smooth muscle cells
MCT-induced PAH had prominent PCNA positive cells in 
the medial wall of pulmonary arterioles. Simvastatin, silde-
nafil and combination therapy showed significant reduction 
in PCNA-positive cells in MCT-induced PAH (Fig. 4). How-
ever, TUNEL-positive cells for detecting apoptosis was rarely 
seen in both MCT-induced PAH and drug treated groups 
(Fig. 4). 
Fig. 1. Right systolic ventricle pressure. Simvastatin (SIM), sildena-
fil (SIL) and combination therapy (SIM+SIL) prevents the develop-
ment of pulmonary arterial hypertension in monocrotaline (MCT) 
treated rats. However, combination therapy does not show additive 
effects over monotherapy. Values are expressed as mean±SD. *p< 
0.05 vs. control, †p<0.05 vs. MCT. RV: right ventricle.
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Fig. 2. Ratio of the right ventricle (RV) to left ventricle (LV) plus sep-
tum weight. Monocrotaline (MCT)-induced RV hypertrophy was at-
tenuated after simvastatin (SIM), sildenafil (SIL) and combination 
therapy (SIM+SIL). However, combination therapy did not show ad-
ditional additive effects over monotherapy. Values are expressed as 
mean±SD. *p<0.05 vs. control, †p<0.05 vs. MCT.
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Fig. 3. Medial wall thickness of pulmonary arterioles. Thickened me-
dial wall in monocrotaline (MCT) treatment group was significantly 
reduced in simvastatin (SIM), sildenafil (SIL) and combination ther-
apy (SIM+SIL). However, combination therapy did not show addition-
al additive effects over monotherapy. Values are expressed as mean 
±SD. *p<0.05 vs. control, †p<0.05 vs. MCT.
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Western blotting of endothelial nitric oxide synthase
As can be seen in Fig. 5, eNOS expression in the lung was 
significantly depressed after 3 weeks of MCT treatment (p< 
0.05). The expression of eNOS was significantly up-regulat-
ed in the treated groups, compared to that of the MCT group 
(p<0.05). In particular, eNOS expression in sildenafil-treated 
group was much higher than that of the combination thera-
py group (p<0.05) (Fig. 5).
Discussion
Our data show that simvastatin and sildenafil have thera-
peutic effects in MCT-induced PAH in rats, even though sim-
vastatin and sildenafil combination therapy has not shown 
greater clinical benefits than monotherapy with either agent. 
Simvastatin has potent antiproliferative and antiapoptotic 
effects on vascular smooth muscle cells, enhances production 
of eNOS and exerts anti-inflammatory effects in the cardio-
vascular system.
17-19) In animal studies, simvastatin could re-
verse or attenuate pulmonary hypertension.
9)20)21) A clinical 
study with small groups of patients demonstrated improve-
ments in 6 min-walk performance and hemodynamics in 
patients receiving simvastatin daily.
22) Our studies have dem-
onstrated reduction of RVP, reduced cellular proliferation 
and enhanced eNOS expression in simvastatin treated group, 
which are consistent with the results of previous studies.
Sildenafil is a selective PDE-5 inhibitor, which exerts relax-
ation of vascular smooth muscle cells by inhibiting cyclic gua-
nosine monophosphate (cGMP) metabolism. Sildenafil has 
been shown to have beneficial effects in animal and clinical 
studies.
11)12)16) However, although this treatment may slow dis-
ease progression, it does not cure the condition. Therefore, com-
bination of two or more drugs with different mechanisms are 
being widely used.
23)24) However, the effect combining simv-
astatin and sildenafil in PAH is not certain. 
In this study, we did not determine the additional benefits 
of combination therapy over monotherapy with either simvas-
tatin or sildenafil. Consistent with our results, Satoh and Sa-
toh
25) reported that the combination of simvastatin (2 mg/kg/ 
day) and sildenafil (5 mg/kg/day) did not show additive ef-
fects on MCT-induced PAH. It may be due to the low dosage 
of sildenafil administered. However, Liu et al.
26) reported that 
low dose sildenafil (1.75 mg/kg/day) can also prevent and re-
verse pulmonary hypertension effectively. Therefore, further 
studies are necessary to determine the effective dosage of sil-
denafil in PAH in animal models. 
In addition, two other studies showed beneficial effects of 
combination therapy.
27)28) Recent studies demonstrated that 
combining simvastatin (20 mg/kg/day) and sildenafil (75 
mg/kg/day) in hypoxic animal PAH models had greater th-
erapeutic effects than using either treatment alone and that 
combination therapy augmented the levels of lung cGMP 
twice more than monotherapy did, even though the dosage of 
the two drugs is high enough to reach hepatotoxicity.
27) More-
PCNA
TUNEL
Control                                   MCT                             MCT+SIM                       MCT+SIL                      MCT+SIM+SIL
Fig. 4. Immunohistochemical stains of proliferating cell nuclear antigen (PCNA) and terminal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL). Monocrotaline (MCT)-induced pulmonary hypertension showed prominent smooth muscle cell proliferation of the pulmonary ar-
tery. Simvastatin (SIM), sildenafil (SIL) and combination therapy (SIM+SIL) reduced cellular proliferation. TUNEL positive cells were not evident 
in all groups. Arrowheads, PCNA-positive cells.
Fig. 5. Western blots for eNOS in the lung. Expression of lung eNOS 
was significantly diminished in the monocrotaline (MCT)-induced pul-
monary hypertension. However, eNOS expression was normalized 
to the control level by simvastatin (SIM) and sildenafil (SIL) treat-
ment. However, combination therapy (SIM+SIL) did not show addi-
tional additive effects over monotherapy. Values are expressed as 
mean±SD. *p<0.05 vs. control, †p<0.05 vs. MCT, ‡p<0.05 vs. SIM and 
combination. eNOS: endothelial nitric oxide synthase.
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over, in MCT-induced PAH model, the combination of low 
dose of simvastatin (7 mg/kg/day) and sildenafil (20 mg/kg/
day) had greater therapeutic effects than monotherapy in 
which the dosages of two drugs were similar with that of our 
study.
28) In this study, each drug increased nitric oxide and 
cGMP significantly. The combination therapy did not show 
additive benefits, even though there were great improvements 
in hemodynamic and histologic changes. Consistent with pre-
vious studies, our study also showed that eNOS expression was 
higher in monotherapy with sildenafil than combination ther-
apy. Therefore, further studies, using multiple animal models, 
different dosage of drugs and different length of follow up are 
needed in order to assess the effectiveness of combination therapy. 
It is well known that MCT-induced PAH is developed by 
abnormal cellular proliferation of vascular endothelial and 
smooth muscle cells.
1) Thus, many drugs are focused on re-
ducing cellular proliferation via apoptosis. In this study, PC-
NA-positive staining cells in MCT rats were prominent but 
rarely seen in simvastatin, sildenafil and their combination 
therapies. It indicates that simvastatin, sildenafil and their 
combination therapies effectively reduce cellular prolifera-
tions. Several studies showed that apoptosis is one of the most 
important mechanisms in attenuating PAH.
9)10) However, we 
did not find significant TUNEL-positive cells in MCT-induc-
ed PAH and mono- and combined therapy groups with sim-
vastatin and sildenafil. These results may be due to intensive 
proliferation of smooth muscle cells that developed in the 
early phase of MCT injection.
29) In addition, the apoptotic pro-
cess was more prominent in the early phase of the therapeu-
tic trial.
10) From these results, the timing of treatment appears 
to be very important in the therapy of PAH. 
One of the beneficial effects of simvastatin and sildenafil is 
increased eNOS expression.
11)12) This study also showed that 
the treatment with simvastatin or sildenafil significantly in-
creased the expression of eNOS, compared to MCT-induced 
PAH rat. Among them, sildenafil induced the most up-reg-
ulation in eNOS expression.
In summary, monotherapy with either simvastatin or silde-
nafil and combination therapy with both agents attenuated 
MCT-induced PAH. However, combination therapy with sim-
vastatin and sildenafil was not more effective than monother-
apy with either agent. Further studies with different design, in-
cluding PAH models, drug dosages and duration of treatments, 
are required to confirm the beneficial effects of the combina-
tion therapy. 
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